Drugs · acquisition-cost intelligence
Exelon
rivastigmine· ingredient rivastigmineAnticholinesterases· RIVASTIGMINE 13.3 mg/24h; RIVASTIGMINE 4.6 mg/24h; RIVASTIGMINE 9.5 mg/24h
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.81
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 8 weeks.
2025-09-172026-05-20
Same-ingredient options by acquisition cost
Other rivastigmine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Rivastigmine Tartrate | $0.16229 | −$1.65 |
| Rivastigmine Tartrate | $0.16572 | −$1.65 |
Medicare Part D coverage · CY2026
On 318 plan formularies · typical tier 4
Prior auth 0% · Step therapy 2% · Quantity limit 66% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.